Showing 1-10 of 862 results for "".
Harnessing the Power of Humor for Psoriasis
https://practicaldermatology.com/topics/psoriasis/harnessing-the-power-of-humor-for-psoriasis/23007/Humor can create positive changes in our thoughts, feelings, behaviors, and biochemistry and can also influence how patients cope.Humira Approved for HS, NewDerm LIVE Hits Hollywood
https://practicaldermatology.com/topics/psoriasis/dermwiretv-humira-approved-for-hs-newderm-live-hits-hollywood/18831/AbbVie's Humira has become the first and only FDA-approved therapy for adults with moderate to severe hidradenitis suppurativa. NewDermLIVE, a new meeting for dermatologists new to practice—and those not so new to practice—has brought a new kind of meeting into the dermatology space. Solta MedicaFirst Medication for Severe Frostbite; Biosimilar to Humira with Interchangeability Status Approved; Two Late-Stage AD Candidates Advance
https://practicaldermatology.com/series/dermwire-tv/first-medication-for-severe-frostbite-biosimilar-to-humira-with-interchangeability-status-approved-two-late-stage-ad-candidates-advance/20267/In this episode of DermWireTV, the first medication to treat severe frostbite is approved by the FDA; the first high-concentration biosimilar to Humira with interchangeability status will soon be available in the US; and two companies with late-stage atopic dermatitis candidates provide key updates."Human Sigma" and the Aesthetic Practice
https://practicaldermatology.com/topics/practice-management/-human-sigma-and-the-aesthetic-practice/19212/Edwin Williams, MD, FACS discusses how "Human Sigma" has influenced his practice and improved practice efficiency.Scientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoDermWireTV: LEO Science & Tech Hub, Allergan/SkinBetter DREAM Initiative, San Diego Dermatology Symposium
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-leo-pharma-science-tech-hub-allerganskinbetter-dream-initiative-san-diego-dermatology-symposium/19856/Innovation Endeavors and the LEO Science & Tech Hub kick off a Deep Life Challenge program. Allergan Aesthetics, an AbbVie company, and Skinbetter Science launch a new long-term, educational initiative: The DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative. The San Diego DermatologyDermWireTV: International Launch of AviClear; Biological Effects of Air Pollution on Human Skin; New AAD Guidelines for Acne Care
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-international-launch-of-aviclear-biological-effects-of-air-pollution-on-human-skin-new-aad-guidelines-for-acne-care/20261/In this episode of DermWireTV, we report on the international launch of the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. An expert discusses a recent study that examines the biological effects of air pollution on human skin equivalents. For th- FDA Approves New Humira Biosimilar for Multiple Inflammatory Conditionshttps://practicaldermatology.com/news/fda-approves-new-adalimumab-adbm-formulation-multiple-inflammatory-conditions/2462933/Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company, the approval enables an expansion of treatment options for chronic inflammatory diseases. This formulation…
- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on treatment with ruxolit…
- Alvotech and Teva Announce US Approval of Simlandi, a Biosimilar to Humirahttps://practicaldermatology.com/news/alvotech-and-teva-announce-us-approval-of-simlandi-a-biosimilar-to-humira/2462250/Alvotech and Teva Pharmaceuticals announced the FDA approval of Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to blockbuster drug Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthri…
- Prev
- Next